Hologic acquires Diagenode for $159 million

By LabPulse.com staff writers

March 1, 2021 -- Hologic has purchased European molecular diagnostic assay and epigenetic product developer Diagenode for $159 million in a deal that will expand Hologic's molecular diagnostics business internationally.

Diagenode offers clients more than 30 polymerase chain reaction (PCR) tests, as well as a portfolio of devices, kits, reagents, and antibodies for DNA and RNA analysis.

The two firms have had a partnership since 2016 and have collaborated on Panther Fusion assays for group B Streptococcus and Bordetella. Diagenode generated more than $30 million in revenue in the last year, Hologic said.

Hologic wraps up Biotheranostics acquisition
Hologic has completed the acquisition of cancer test developer Biotheranostics. Hologic is gaining access to two laboratory-developed tests as part of...
Hologic inks deal with Google to unite cloud with diagnostics
Hologic has announced a collaboration with Google designed to advance the potential of digital diagnostics for cervical cancer screening by making Google...
Diagnostics growth drives Hologic's Q1 results higher
Strong growth in its molecular diagnostics business -- with revenues almost tripling due to the COVID-19 pandemic -- helped drive first-quarter preliminary...
Hologic buys Biotheranostics molecular testing firm
Hologic continues to start 2021 with a bang. The company announced on January 5 that it is acquiring Biotheranostics, a developer of molecular tests for...
FDA OK's new claim for Hologic's HIV assay
The U.S. Food and Drug Administration (FDA) has approved Hologic's diagnostic claim for its HIV-1 viral load monitoring assay, the Aptima HIV-1 Quant...

Copyright © 2021 LabPulse.com

Last Updated bc 3/2/2021 7:12:15 AM